Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1032

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: placebo
DRUG: placebo
DRUG: placebo
DRUG: tiotropium Respimat® low dose
DRUG: placebo
DRUG: tiotropium Respimat® high dose
DRUG: 50 mcg salmeterol HFA MDI
DRUG: placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]